#Obesity medicine
Chronic weight management as a clinical specialty.
MASLD treatment: what a 2026 review found
A Gut and Liver review maps current MASLD treatment options and a growing pipeline, from lifestyle change to GLP-1 agonists and thyroid receptor drugs.
Oral incretin therapies for weight loss
Oral semaglutide and orforglipron bring GLP-1 based weight management into tablet form. Here is what the evidence does and does not show.
GLP-1 FAERS safety signals explained
A 2026 pharmacovigilance paper examined 243,114 FAERS reports for GLP-1 agents. Tirzepatide led at 133,100. What the signal patterns mean.
GLP-1 Drugs in Children Ages 8-11: Trends
A 3.5-million-child Pediatrics study found GLP-1 prescriptions for 8-to-11-year-olds grew 310-fold from 2019 to 2026, all off-label.
GLP-1 Receptor Agonists and Sleep Apnea
Tirzepatide holds a US FDA approval for sleep apnea backed by SURMOUNT-OSA data. Here is what the evidence supports for the GLP-1 receptor agonist class.
Semaglutide, obesity, and chronic migraine
A 2026 letter in Headache argues semaglutide may break a loop in which obesity worsens migraine and fasting-driven avoidance triggers more attacks.
Semaglutide's direct reproductive effects
A 2026 rat study found semaglutide affects gonads beyond weight loss: androgens protected in males, reproductive hormones reduced in females.
Incretin drugs: outcomes before weight loss
A 2026 review ranks incretin therapies by CV mortality evidence first, weight loss second, and maps drug choice to patient phenotype via receptor pharmacology.
Lilly and the Medicare GLP-1 bridge program
The Medicare GLP-1 Bridge launched July 2026 at a $50 monthly copay. Lilly's Q2 numbers show the scale analysts are mapping against it.
Weight Regain After Stopping GLP-1 Drugs
A 2026 Bayesian meta-analysis maps how quickly body weight returns after stopping semaglutide or tirzepatide and what the trajectory looks like over time.
Tirzepatide powder: what the label says
Forum questions about reconstituting tirzepatide powder reveal a key fact: FDA-approved tirzepatide is supplied ready-to-inject, not as a lyophilized powder.
Tirzepatide vs semaglutide: meta-analysis
A 2026 meta-analysis in Clinical Obesity pooled head-to-head and indirect trial data comparing tirzepatide and semaglutide for weight loss.